AOD-9604 in Şirvan — Fat Loss Peptide Research Guide
AOD-9604 research guide for Şirvan. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Şirvan looking to source AOD-9604, the key fact to understand is that this compound is available only through an online research supply market. This concentration of supply in online vendors is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. What reliably differentiates top AOD-9604 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. What follows is a practical research guide built specifically around AOD-9604, covering everything a Şirvan researcher needs before placing a first order.
Understanding AOD-9604 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Şirvan researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate AOD-9604 Vendors
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. A COA for AOD-9604 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. For Şirvan researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before committing to research quantities is the accepted approach among experienced researchers. For Şirvan researchers making a first AOD-9604 purchase: work through this evaluation framework first, start with a modest quantity, and verify batch traceability on arrival before use.
Order AOD-9604 — ships to Şirvan
COA-verified · International tracking · Research grade
AOD-9604 is available for research use only and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — equivalent to 25mcg per unit on an insulin syringe. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Researchers combining AOD-9604 with other compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
